14 апр 2014 г. - FDA finalized the proposed class-wide safety labeling changes for all extended-release and long-acting (ER/LA) opioid analgesics, and responded to two citizen petitions regarding labeling for neonatal opioid withdrawal syndrome (NOWS).

Добавлено на ленту времени:

Opioids and the FDA

ByAnastasia

13 ноя 2018

0

0

520

Дата: